# US 6,723,697 B2 · IL-16 antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,723,697 B2
- Document ID: US6723697B2
- Status: Granted
- Kind: B2
- Application number: 09/929,922
- Filed: 2001-08-15
- Published: 2003-01-23
- Granted: 2004-04-20
- Earliest claimed: 1999-08-05
- Assignees: Research Corporation Technologies, Inc.
- Inventors: David M. Center; William W. Cruikshank; Hardy Kornfeld
- Web page: https://patentgrep.com/patent/US6723697B2

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 5/1013: {the side chain containing O or S as heteroatoms, e.g. Cys, Ser}
- C07K 14/70514: {CD4}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

In accordance with the present invention, novel IL-16 antagonists, preferably peptides derived from CD4, have been isolated and synthesized. These peptides possess IL-16 antagonistic properties including the ability to selectively bind to IL-16 and inhibit IL-16-mediated biological activity. The peptides comprise specific portions of the native human CD4 receptor and variations thereof and therefore are non-immunogenic when administered to humans. The present invention also provides compositions containing at least one IL-16 antagonist peptide which can inhibit, suppress or cause the cessation of at least one IL-16-mediated biological activity in mammals, including humans. The present invention provides a method and composition for treating inflammation associated with disease states such as asthma, rheumatoid arthritis, inflammatory bowel disease (IBD) and systemic lupus (SLE) in mammals such as, for example, humans.

## Claims

### Claim 1

An isolated IL-16 antagonist peptide consisting of CLLS (SEQ ID NO:2).

### Claim 2

An isolated IL-16 antagonist peptide selected from the group consisting of WQCLLS (SEQ ID NO:4), WQALLS (SEQ ID NO:5), VVQVVA (SEQ ID NO:9) or VKQVVA (SEQ ID NO:10).

### Claim 3

An isolated IL-16 antagonist peptide consisting of GMWQCLLS (SEQ ID NO:13).

### Claim 4

An isolated peptide consisting of GMWQCLLSDSGQVLLE (SEQ ID NO:12).

### Claim 5

An isolated peptide consisting of any one of TGLWQCLLSEGD (SEQ ID NO:14) or VSEEQKVVQVVA (SEQ ID NO:15).

### Claim 6 (depends on 1, 2, 3, 4, 5)

A pharmaceutical composition comprising the peptide of any one of claims 1-5, and a pharmaceutically acceptable carrier.